Is a complete CVKD research report available?

No complete published report is available for Cadrenal Therapeutics, Inc. (CVKD) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Cadrenal Therapeutics, Inc. (CVKD)

NASDAQ: CVKD · USD

$2.09

+0.12 (+6.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first CVKD analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	6M
Net income (ttm)	-11.9M
EPS (ttm)	-$5.57
Shares out	2.9M
Volume	17,769.479
Beta	1.75
Price target	$27.7	+1223.9%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -11.9M
EPS (ttm): -$5.57
Market cap: 6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All CVKD indicators

Market & fundamental data

Available fields

183

Groups with data

Currency

USD

Showing 183 of 183 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001937993
Company name	Cadrenal Therapeutics, Inc.
Country	United States
Country code	US
Cusip	127636207
Employees	5
Employees Change	1%
Employees Change Percent	25
Enterprise value	$3.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2023-01-20
Isin	US1276362076
Last refreshed	2026-07-31
Market cap	$6M
Market cap category	Nano-Cap
Price	$2.09
Price currency	USD
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	2834
Symbol	CVKD
Website	https://www.cadrenal.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-210.4%
FCF yield	-193.91%
P/B ratio	2.75x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-11.9M
Net Income Growth Quarters	2%
Net Income Growth Years	0%
Profit Per Employee	$-2.4M
ROA	-139.2
ROCE	-670.4
ROE	-300.6
ROIC	-190.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-80.79%
Cagr3y	-45.42%
EPS Growth Quarters	4
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$2.9M
Cash	$2.3M
Current Assets	$2.9M
Current Liabilities	$1.1M
Debt	$0
Equity	$1.8M
Liabilities	$1.1M
Long Term Assets	$6,786
Long Term Liabilities	$0
Net Cash	$2.3M
Net Cash By Market Cap	$40.85
Net Cash Growth	-68.54%
Net Debt Equity	$-1.28
Tangible Book Value	$1.8M
Tangible Book Value Per Share	$0.72
WACC	13.88

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.68
Net Working Capital	$-517,808
Quick ratio	2.17
Working Capital	$1.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-50.99%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-80.77%
200-day SMA	6.93
3Y total return	-83.75%
50-day SMA	3.39
50-day SMA vs 200-day SMA	50under200
All Time High	101.3
All Time High Change	-97.94%
All Time High Date	2023-01-20
All Time Low	1.86
All Time Low Change	12.37%
All Time Low Date	2026-07-23
ATR	0.3
Beta	1.75
Beta1y	2.6
Beta2y	1.3
Ch YTD	-69.17
High	2.09
High52	14.64
High52 Date	2025-10-03
High52ch	-85.72%
Low	1.96
Low52	1.86
Low52 Date	2026-07-23
Low52ch	12.37%
Ma50ch	-38.37%
Premarket Change Percent	1.52
Premarket Price	$2
Premarket Volume	1,200
Price vs 200-day SMA	-69.85%
RSI	32.34
RSI Monthly	31.96
RSI Weekly	27.36
Sharpe ratio	-1.17x
Sortino ratio	-1.62
Total Return	-50.99%
Tr YTD	-69.17
Tr1m	-30.79%
Tr1w	2.96%
Tr3m	-62.61%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Count Top	1
Analyst Price Target Top	$13
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-1.87
Operating Income	$-12M
Price target	$27.67
Price Target Change	$1,224
Price Target Change Top	$522

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,442,714%
Float Percent	85.16%
Shares Insiders	14.84%
Shares Institutions	3.4%
Shares Out	2,868,247
Shares Qo Q	13.41%
Shares Yo Y	50.99%
Short Float	2.28%
Short Ratio	0.59
Short Shares	1.94

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-12.6M
Adjusted OCF	-12,598,623
Average Volume	69,538.5x
Bv Per Share	0.72
CAPEX	$-1,853
Ch1m	-30.79
Ch1w	2.96
Ch1y	-80.77
Ch3m	-62.61
Ch3y	-83.75
Ch6m	-71.98
Change	6.09%
Change From Open	3.98
Close	1.97
Days Gap	2.03
Depreciation Amortization	1,912
Dollar Volume	37,138.2
Earnings Date	2026-08-07
Earnings Time	bmo
EBIT	$-12M
EBITDA	$-12M
EPS	$-5.57
F Score	1
FCF	$-11M
FCF EV Yield	-327.83x
FCF Per Share	$-3.82
Financing CF	5,929,046
Fiscal Year End	December
Founded	2,022
Investing CF	-1,853
Ipr	-60.6
Iprfo	-97.7
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Date	2024-08-20
Last Split Type	Reverse
Last10k Filing Date	2026-03-31
Ma150	5.45
Ma150ch	-61.62%
Ma20	2.47
Ma20ch	-15.32%
Net CF	-5,027,935
Next Earnings Date	2026-08-10
Open	2.01
Optionable	No
Position In Range	100
Post Close	2.09
Postmarket Change Percent	-5.26
Postmarket Price	$1.98
Ppne	4,619
Pre Close	1.97
Price Date	2026-07-30
Ptbv Ratio	3.14
Relative Volume	0.26x
Share Based Comp	1,643,495
Tr6m	-71.98%
Us State	Florida
Volume	17,769.5

Cadrenal Therapeutics, Inc. (CVKD)

Coverage state: Market snapshot only — no published research

Generate the first CVKD analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · CVKD

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CVKD indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on CVKD

Frequently asked questions